Home / Auditor changes / Benitec Biopharma Inc.
Filed 2026-09-30 路 Form 8-K 路 Accession 0001193125-26-409052 small
Price before filing: $9.75 (2026-09-29 close, split/dividend-adjusted)
Market cap at flag: $465.6M (2026-09-30) 路 Latest: $377.6M (2026-10-16)
| Window | BNTC | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | pending | pending | until 2026-10-30 | |
| 90 days | pending | pending | until 2026-12-29 | |
| 180 days | pending | pending | until 2027-03-29 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"(the "Company") filed on September 24, 2026, the Company reported the approval of the engagement of Ernst & Young LLP ("EY") as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2027."
Quoted from the filing. Source
The company changed its outside auditor (8-K Item 4.01). A dismissal or resignation, especially near an annual report or with reported disagreements, is a warning sign. Changes caused by audit firms merging are usually routine.
Type: changed
Disagreements reported: no
New auditor: Ernst & Young LLP
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.